Immunotherapy and NSCLC: The Long and Winding Road

Open AccessEditorial

by

Antonio Rossi

Therapeutic Science and Strategy Unit, IQVIA, Via Fabio Filzi 29, 20124 Milan, Italy

Cancers 2020, 12(9), 2512; https://doi.org/10.3390/cancers12092512

Submission received: 26 August 2020 / Accepted: 2 September 2020 / Published: 4 September 2020

(This article belongs to the Special Issue PD-L1/PD1 Modulation Mechanisms in Lung Cancer: From Basic to Translational Evidences)

Download

Browse Figure

Versions Notes

Excerpt

Note: In lieu of an abstract, this is an excerpt from the first page.

Lung cancer is one of the most incident tumors worldwide, characterized by a very bad prognosis due to its high mortality even in early stages [...]

MDPI and ACS Style

Rossi, A. Immunotherapy and NSCLC: The Long and Winding Road. Cancers 2020, 12, 2512. https://doi.org/10.3390/cancers12092512

AMA Style

Rossi A. Immunotherapy and NSCLC: The Long and Winding Road. Cancers. 2020; 12(9):2512. https://doi.org/10.3390/cancers12092512

Chicago/Turabian Style

Rossi, Antonio. 2020. "Immunotherapy and NSCLC: The Long and Winding Road" Cancers 12, no. 9: 2512. https://doi.org/10.3390/cancers12092512

APA Style

Rossi, A. (2020). Immunotherapy and NSCLC: The Long and Winding Road. Cancers, 12(9), 2512. https://doi.org/10.3390/cancers12092512

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.